OMA3
1.11.2022 20:46:43 CET | Business Wire | Press release
Today, OMA3™ (Open Metaverse Alliance), an association based in Zug, Switzerland, is announcing open membership to its first working groups at Web Summit, Europe’s largest tech conference.
Initial working group participants include some of the biggest and most innovative names in the space such as Animoca Brands, Alien Worlds, Dapper Labs, MetaMetaverse, SPACE Metaverse, SuperWorld, The Sandbox, Upland, Voxels, Unstoppable Domains, and Wivity (the agent to the consortium).
One of the core values of the metaverse is celebrating the decentralization of not only assets but power and influence as well. OMA3 achieves this by ensuring virtual land, identities, digital assets, ideas, and services are highly interoperable between platforms and transparent to all communities. OMA3’s Portaling and Mapping Working Group will create standards that allow users to port between virtual worlds. The Asset Transfer Working Group will standardize infrastructure for moving digital assets between virtual worlds. The Legal Working Group will examine the protection and fair use of intellectual property in Web3 applications and monitor developments in the regulatory environment. Companies wishing to participate in these working groups are invited to join OMA3 as a Creator Member on its website- OMA3.org.
As the metaverse continues to grow and develop at a rapid pace, the association will continue to nurture an open, interoperable metaverse by launching more working groups in areas such as participant safety, privacy, and cybersecurity.
Dirk Lueth, Co-founder & Co-CEO, Upland, Founding Member and Chairperson of OMA3 said, “The vision of OMA3 is to move from a platform-controlled Web2-world to a user-centric Web3-Metaverse. To achieve this, we have formed an alliance of Web3 companies who want to solve interoperability challenges for the metaverse, and we aim to leverage the alliance’s knowledge and web3 native insight to help propose and set the operating standard for interoperability in the metaverse.”
Batis Samadian, Founder & CEO, SPACE, Founding Member, and Vice Chair of OMA3 said, “Decentralization and interoperability require coordination to be successful. We are pleased that the OMA3 idea we hatched in the early days has resonated so well with the industry.”
All members of OMA3 have a shared belief in an Open Metaverse without restraining walls, where individual platforms are interconnected and fully interoperable so users can move their digital assets freely across worlds. To realize this goal, OMA3 has been formed and looks forward to members joining its mission.
Sébastien Borget, Co-Founder and COO of The Sandbox and Founding Member of OMA3 said, “within the Open Metaverse, digital assets freely move across OMA3 virtual worlds, enjoying increased security and better asset tracking across worlds. With these shared standards, users will be able to take digital items that they own from one metaverse to another, enabling a universe of interconnected virtual worlds that prioritizes user experience and ownership over platform dominance and censorship.”
Saro McKenna, CEO of Alien Worlds and Founding Member of OMA3 said, “OMA3’s vision centers on striving to create an open metaverse that is also community run, decentralized and indexable, where users will be able to own and use their digital assets (e.g. NFTs), identity and reputation in a frictionless way across multiple platforms. In OMA3’s vision users are in control of their assets, not platform owners, while ideas and services are based on the foundation of decentralization and interoperability to optimize for individual freedom, social, economic, and other sustainable outcomes.”
OMA3 is committed to ensuring data is permissionless, interoperable, and fully user-controlled, with DAO governance-centered principles of inclusiveness, transparency, and decentralization. As such, OMA3 is open to all Web3 metaverse builders; companies can join as creators or community members. To learn more about participation, please visit www.oma3.org.
About OMA3
OMA3, (Open Metaverse Alliance) is a consortium comprised of leading metaverse native companies The Sandbox, Animoca Brands, Alien Worlds, Dapper Labs, Decentraland, MetaMetaverse, Space, SuperWorld, Upland, Voxels, Unstoppable Domains, and Wivity. OMA3 seeks to ensure virtual land, digital assets, ideas, and services are highly interoperable between platforms and transparent to all communities.
Twitter: twitter.com/oma3dao
Website: www.oma3.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005819/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
